{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T10:31:04Z","timestamp":1788690664218,"version":"build-2803163510"},"reference-count":108,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s40266-016-0402-1","type":"journal-article","created":{"date-parts":[[2016,10,13]],"date-time":"2016-10-13T12:51:47Z","timestamp":1476363107000},"page":"711-723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Autoimmune Blistering Diseases in the Elderly: Clinical Presentations and Management"],"prefix":"10.1007","volume":"33","author":[{"given":"Minhee","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Borradori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9d\u00e9e F.","family":"Murrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,13]]},"reference":[{"issue":"2","key":"402_CR1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00128071-200910020-00001","volume":"10","author":"MA Farage","year":"2009","unstructured":"Farage MA, Miller KW, Berardesca E, Maibach HI. Clinical implications of aging skin: cutaneous disorders in the elderly. Am J Clin Dermatol. 2009;10(2):73\u201386.","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"402_CR2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2165\/00002512-200421120-00002","volume":"21","author":"WJ Loo","year":"2004","unstructured":"Loo WJ, Burrows NP. Management of autoimmune skin disorders in the elderly. Drugs Aging. 2004;21(12):767\u201377.","journal-title":"Drugs Aging"},{"issue":"1","key":"402_CR3","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2133.2004.06006.x","volume":"151","author":"RM Vodegel","year":"2004","unstructured":"Vodegel RM, Jonkman MF, Pas HH, de Jong MC. U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases. Br J Dermatol. 2004;151(1):112\u20138.","journal-title":"Br J Dermatol"},{"issue":"4","key":"402_CR4","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/0190-9622(90)70094-X","volume":"22","author":"WR Gammon","year":"1990","unstructured":"Gammon WR, Kowalewski C, Chorzelski TP, Kumar V, et al. Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. J Am Acad Dermatol. 1990;22(4):664\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"402_CR5","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/bjd.12479","volume":"169","author":"AM Poot","year":"2013","unstructured":"Poot AM, Diercks GF, Kramer D, et al. Laboratory diagnosis of paraneoplastic pemphigus. Br J Dermatol. 2013;169(5):1016\u201324.","journal-title":"Br J Dermatol"},{"key":"402_CR6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/978-3-662-45698-9_31","volume-title":"Blistering diseases","author":"L Borradori","year":"2015","unstructured":"Borradori L, Murrell DF, Hall RP 3rd. Bullous pemphigoid (cutaneous pemphigoid): the spectrum of clinical presentations. In: Murrell DF, editor. Blistering diseases. Sydney: Springer, Inc.; 2015. p. 335\u201342."},{"issue":"4","key":"402_CR7","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2009.09300.x","volume":"161","author":"G Marazza","year":"2009","unstructured":"Marazza G, Pham HC, Scharer L, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol. 2009;161(4):861\u20138.","journal-title":"Br J Dermatol"},{"issue":"5","key":"402_CR8","first-page":"434","volume":"7","author":"F Bertram","year":"2009","unstructured":"Bertram F, Brocker EB, Zillikens D, Schmidt E. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges. 2009;7(5):434\u201340.","journal-title":"J Dtsch Dermatol Ges."},{"key":"402_CR9","doi-asserted-by":"crossref","first-page":"a180","DOI":"10.1136\/bmj.a180","volume":"337","author":"SM Langan","year":"2008","unstructured":"Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris-incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180.","journal-title":"BMJ"},{"issue":"2 Pt 1","key":"402_CR10","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0190-9622(99)70061-7","volume":"41","author":"M Jung","year":"1999","unstructured":"Jung M, Kippes W, Messer G, et al. Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol. 1999;41(2 Pt 1):266\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"402_CR11","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1365-4632.2009.04345.x","volume":"49","author":"A Baican","year":"2010","unstructured":"Baican A, Baican C, Chiriac G, et al. Pemphigus vulgaris is the most common autoimmune bullous disease in northwestern Romania. Int J Dermatol. 2010;49(7):768\u201374.","journal-title":"Int J Dermatol"},{"issue":"1","key":"402_CR12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archderm.1995.01690130050009","volume":"131","author":"P Bernard","year":"1995","unstructured":"Bernard P, Vaillant L, Labeille B, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions: Bullous Diseases French Study Group. Arch Dermatol. 1995;131(1):48\u201352.","journal-title":"Arch Dermatol"},{"key":"402_CR13","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/jid.2012.35","volume":"132","author":"P Joly","year":"2012","unstructured":"Joly P, Baricault S, Sparsa A, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol. 2012;132:1998\u20132004.","journal-title":"J Invest Dermatol."},{"issue":"8","key":"402_CR14","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archderm.131.8.957","volume":"131","author":"D Zillikens","year":"1995","unstructured":"Zillikens D, Wever S, Roth A, et al. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol. 1995;131(8):957\u20138.","journal-title":"Arch Dermatol"},{"key":"402_CR15","first-page":"687","volume-title":"Blistering diseases","author":"E Schmidt","year":"2015","unstructured":"Schmidt E, Borradori L, Joly P. Epidemiology of autoimmune bullous diseases. In: Murrell DF, editor. Blistering diseases. Sydney: Springer, Inc.; 2015. p. 687\u201394."},{"issue":"2","key":"402_CR16","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2005.06662.x","volume":"153","author":"VS Gudi","year":"2005","unstructured":"Gudi VS, White MI, Cruickshank N, et al. Annual incidence and mortality of bullous pemphigoid in the Grampian region of the north-east Scotland. Br J Dermatol. 2005;153(2):424\u20137.","journal-title":"Br J Dermatol"},{"issue":"2","key":"402_CR17","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-2133.2011.10413.x","volume":"165","author":"B Cortes","year":"2011","unstructured":"Cortes B, Marazza G, Naldi L, et al. Mortality of bullous pemphigoid in Switzerland: a prospective study. Br J Dermatol. 2011;165(2):368\u201374.","journal-title":"Br J Dermatol"},{"key":"402_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-195302000-00001","volume":"32","author":"WF Lever","year":"1953","unstructured":"Lever WF. Pemphigus. Medicine. 1953;32:1\u2013123.","journal-title":"Medicine."},{"issue":"7","key":"402_CR19","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archderm.138.7.903","volume":"138","author":"B Rzany","year":"2002","unstructured":"Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol. 2002;138(7):903\u20138.","journal-title":"Arch Dermatol"},{"key":"402_CR20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-4632.2004.02457.x","volume":"45","author":"PM Lamb","year":"2006","unstructured":"Lamb PM, Abell E, Tharp M, et al. Prodromal bullous pemphigoid. Int J Dermatol. 2006;45:209\u201314.","journal-title":"Int J Dermatol"},{"key":"402_CR21","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1365-2133.2012.11108.x","volume":"167","author":"R Della Tore","year":"2012","unstructured":"Della Tore R, Combescure C, Cortes B, et al. Clinical presentations and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort. Br J Dermatol. 2012;167:1111\u20137.","journal-title":"Br J Dermatol"},{"issue":"4","key":"402_CR22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamadermatol.2014.51","volume":"150","author":"L Borradori","year":"2014","unstructured":"Borradori L, Joly P. Toward a practical renaming of bullous pemphigoid and all its variants: cutaneous pemphigoid. JAMA Dermatol. 2014;150(4):459.","journal-title":"JAMA Dermatol."},{"key":"402_CR23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clim.2008.04.012","volume":"128","author":"G Zenzo Di","year":"2008","unstructured":"Di Zenzo G, Thoma-Uszynski S, Fontao L, et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol. 2008;128:415\u201326.","journal-title":"Clin Immunol."},{"issue":"3","key":"402_CR24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000106574","volume":"215","author":"N Cordel","year":"2007","unstructured":"Cordel N, Chosidow O, Hellot MF, et al. Risk factors for lethal outcome in patients with bullous pemphigoid. Dermatology. 2007;215(3):187\u201391.","journal-title":"Dermatology"},{"issue":"2","key":"402_CR25","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0923-1811(94)00371-K","volume":"9","author":"H Ogawa","year":"1995","unstructured":"Ogawa H, Sakuma M, Morioka S, et al. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci. 1995;9(2):136\u201341.","journal-title":"J Dermatol Sci"},{"issue":"3","key":"402_CR26","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2133.2011.10386.x","volume":"165","author":"YJ Chen","year":"2011","unstructured":"Chen YJ, Wu CY, Lin MW, et al. Comorbidity profiles among patients with bullous pemphigoid: a nation-wide population-based study. Br J Dermatol. 2011;165(3):593\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"402_CR27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1468-3083.2011.04062.x","volume":"26","author":"K Skandalis","year":"2012","unstructured":"Skandalis K, Spirova M, Gaitanis G, et al. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. 2012;26(2):249\u201353.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"402_CR28","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.2337\/dc11-0804","volume":"34","author":"E Pasmatzi","year":"2011","unstructured":"Pasmatzi E, Monastirli A, Habeos J, et al. Dipeptidyl peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients: report of two cases. Diabetes Care. 2011;34(8):e133.","journal-title":"Diabetes Care"},{"issue":"2","key":"402_CR29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jamadermatol.2013.1073","volume":"149","author":"I Aouidad","year":"2013","unstructured":"Aouidad I, Fite C, Marinho E, et al. A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. JAMA Dermatol. 2013;149(2):243\u20135.","journal-title":"JAMA Dermatol."},{"issue":"1","key":"402_CR30","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3315\/jdcr.2014.1166","volume":"8","author":"A Attaway","year":"2014","unstructured":"Attaway A, Mersfelder TL, Vaishnav S, Baker JK. Bullous pemphigoid associated with dipeptidyl peptidase IV inhibitors: a case report and review of literature. J Dermatol Case Rep. 2014;8(1):24\u20138.","journal-title":"J Dermatol Case Rep."},{"key":"402_CR31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/978-3-662-45698-9_55","volume-title":"Blistering diseases","author":"MN Ramirez-Quizon","year":"2015","unstructured":"Ramirez-Quizon MN, Borradori L, Hall RP 3rd, Murrell DF. Management of bullous pemphigoid. In: Murrell DF, editor. Blistering diseases. Sydney: Springer, Inc.; 2015. p. 543\u201363."},{"issue":"5","key":"402_CR32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","volume":"346","author":"P Joly","year":"2002","unstructured":"Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346(5):321\u20137.","journal-title":"N Engl J Med"},{"issue":"7","key":"402_CR33","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/jid.2008.412","volume":"129","author":"P Joly","year":"2009","unstructured":"Joly P, Roujeau JC, Benichou J, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicentre randomized study. J Invest Dermatol. 2009;129(7):1681\u20137.","journal-title":"J Invest Dermatol."},{"issue":"2","key":"402_CR34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.iac.2012.04.008","volume":"32","author":"JW Frew","year":"2012","unstructured":"Frew JW, Murrell DF. Corticosteroid use in autoimmune blistering diseases. Immunol Allergy Clin N Am. 2012;32(2):283\u201394.","journal-title":"Immunol Allergy Clin N Am."},{"key":"402_CR35","doi-asserted-by":"crossref","unstructured":"Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010;10:CD002292.","DOI":"10.1002\/14651858.CD002292.pub3"},{"issue":"10","key":"402_CR36","first-page":"925","volume":"111","author":"P Morel","year":"1984","unstructured":"Morel P, Guillaume JC. Treatment of bullous pemphigoid with prednisolone only: 0.75\u00a0mg\/kg\/day versus 1.25\u00a0mg\/kg\/day. A multicentre randomized study. Ann Dermatol Venereol. 1984;111(10):925\u20138.","journal-title":"Ann Dermatol Venereol"},{"issue":"1","key":"402_CR37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","volume":"9","author":"D Liu","year":"2013","unstructured":"Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.","journal-title":"Allergy Asthma Clin Immunol."},{"issue":"6","key":"402_CR38","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archderm.1994.01690060083010","volume":"130","author":"DP Fivenson","year":"1994","unstructured":"Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1994;130(6):753\u20138.","journal-title":"Arch Dermatol"},{"issue":"1","key":"402_CR39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/bjd.13729","volume":"173","author":"JR Chalmers","year":"2015","unstructured":"Chalmers JR, Wojnarowska F, Kirtschig G, BLISTER study group, et al. A randomized controlled trial to compare the safety and effectiveness of doxycycline (200\u00a0mg daily) with oral prednisolone (0.5\u00a0mg\u00a0kg(\u22121) daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial. Br J Dermatol. 2015;173(1):227\u201334.","journal-title":"Br J Dermatol"},{"issue":"1","key":"402_CR40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/08916934.2011.606452","volume":"45","author":"A Czernik","year":"2012","unstructured":"Czernik A, Toosi S, Bystryn JC, Grando SA. Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update. Autoimmunity. 2012;45(1):111\u20138.","journal-title":"Autoimmunity."},{"issue":"6","key":"402_CR41","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/ajh.24358","volume":"91","author":"EM Ammann","year":"2016","unstructured":"Ammann EM, Haskins CB, Fillman KM, et al. Intravenous immune globulin and thromboembolic adverse events: a systematic review and meta-analysis of RCTs. Am J Hematol. 2016;91(6):594\u2013605.","journal-title":"Am J Hematol"},{"issue":"4","key":"402_CR42","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jaad.2009.09.045","volume":"64","author":"S Lourari","year":"2011","unstructured":"Lourari S, Herve C, Doffoel-Hantz V, et al. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Am Acad Dermatol. 2011;64(4):773\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"402_CR43","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","volume":"65","author":"M Kasperkiewicz","year":"2011","unstructured":"Kasperkiewicz M, Shimanovich I, Ludwig RJ, et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol. 2011;65(3):552\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"402_CR44","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/archdermatol.2012.1604","volume":"148","author":"VA London","year":"2012","unstructured":"London VA, Kim GH, Fairley JA, Woodley DT. Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol. 2012;148(11):1241\u20133.","journal-title":"Arch Dermatol"},{"issue":"3","key":"402_CR45","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","volume":"71","author":"KK Yu","year":"2014","unstructured":"Yu KK, Crew AB, Messingham KA, et al. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014;71(3):468\u201374.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"402_CR46","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1038\/sj.jid.5700465","volume":"126","author":"KA Rashid","year":"2006","unstructured":"Rashid KA, G\u00fcrcan HM, Ahmed AR. Antigen specificity in subsets of mucous membrane pemphigoid. J Invest Dermatol. 2006;126(12):2631\u20136.","journal-title":"J Invest Dermatol."},{"key":"402_CR47","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cden.2013.07.003","volume":"57","author":"HH Xu","year":"2013","unstructured":"Xu HH, Werth VP, Parisi E, Sollecito TP. Mucous membrane pemphigoid. Dent Clin N Am. 2013;57:611\u201330.","journal-title":"Dent Clin N Am"},{"key":"402_CR48","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1079-2104(99)70194-0","volume":"88","author":"C Scully","year":"1999","unstructured":"Scully C, Carrozzo M, Gandolfo S, et al. Update on mucous membrane pemphigoid: a heterogenous immune-mediated subepithelial blistering entity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88:56\u201368.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"3","key":"402_CR49","first-page":"177","volume":"82","author":"CA Egan","year":"2003","unstructured":"Egan CA, Lazarova Z, Darling TN, et al. Anti-epiligrin cicatricial pemphigoid: clinical findings, immunopathogenesis, and significant associations. Medicine. 2003;82(3):177\u201386.","journal-title":"Medicine."},{"issue":"9271","key":"402_CR50","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/S0140-6736(00)04971-0","volume":"357","author":"CA Egan","year":"2001","unstructured":"Egan CA, Lazarova Z, Darling TN, et al. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet. 2001;357(9271):1850\u20131.","journal-title":"Lancet"},{"issue":"1","key":"402_CR51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1346-8138.2004.tb00497.x","volume":"31","author":"S Matsushima","year":"2004","unstructured":"Matsushima S, Horiguchi Y, Honda T, et al. A case of anti-epiligrin cicatricial pemphigoid associated with lung carcinoma and severe laryngeal stenosis: review of Japanese cases and evaluation of risk for internal malignancy. J Dermatol. 2004;31(1):10\u20135.","journal-title":"J Dermatol"},{"issue":"5","key":"402_CR52","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1001\/jamadermatol.2013.1434","volume":"149","author":"P Bernard","year":"2013","unstructured":"Bernard P, Antonicelli F, Bedane C, et al. Prevalence and clinical significance of anti-laminin 332 autoantibodies detected by a novel enzyme-linked immunosorbent assay in mucous membrane pemphigoid. JAMA Dermatol. 2013;149(5):533\u201340.","journal-title":"JAMA Dermatol."},{"issue":"3","key":"402_CR53","first-page":"191","volume":"17","author":"D Bruch-Gerharz","year":"2007","unstructured":"Bruch-Gerharz D, Hertl M, Ruzicka T. Mucous membrane pemphigoid: clinical aspects, immunopathological features and therapy. Eur J Dermatol. 2007;17(3):191\u2013200.","journal-title":"Eur J Dermatol."},{"key":"402_CR54","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/978-3-662-45698-9_35","volume-title":"Blistering diseases","author":"F Caux","year":"2015","unstructured":"Caux F, Prost-Squarcioni C. Mucous membrane pemphigoid. In: Murrell DF, editor. Blistering diseases. Sydney: Springer, Inc.; 2015. p. 363\u201373."},{"issue":"4\u20135","key":"402_CR55","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3109\/08820538.2011.588660","volume":"26","author":"M Kirzhner","year":"2011","unstructured":"Kirzhner M, Jakobiec FA. Ocular cicatricial pemphigoid: a review of clinical features, immunopathology, differential diagnosis, and current management. Semin Ophthalmol. 2011;26(4\u20135):270\u20137.","journal-title":"Semin Ophthalmol."},{"issue":"4","key":"402_CR56","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/01.md.0000231954.08350.52","volume":"85","author":"M Alexandre","year":"2006","unstructured":"Alexandre M, Brette MD, Pascal F, et al. A prospective study of upper aerodigestive tract manifestations of mucous membrane pemphigoid. Medicine. 2006;85(4):239\u201352.","journal-title":"Medicine."},{"issue":"5 Suppl","key":"402_CR57","first-page":"S128","volume":"46","author":"JC Fueston","year":"2001","unstructured":"Fueston JC, Adams BB, Mutasim DF. Cicatricial pemphigoid-induced phimosis. J Am Acad Dermatol. 2001;46(5 Suppl):S128\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"402_CR58","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/archderm.1991.01680030111016","volume":"127","author":"G Kurzhals","year":"1991","unstructured":"Kurzhals G, Stolz W, Meurer M, et al. Acquired epidermolysis bullosa with the clinical feature of Brunsting-Perry cicatricial bullous pemphigoid. Arch Dermatol. 1991;127:391\u20135.","journal-title":"Arch Dermatol"},{"key":"402_CR59","first-page":"674","volume-title":"Dermatology in general medicine","author":"KB Yancey","year":"1998","unstructured":"Yancey KB. Cicatricial pemphigoid. In: Fitzpatrick TB, Eisen AZ, Wolff K, et al., editors. Dermatology in general medicine. New York: McGraw-Hill; 1998. p. 674\u20139."},{"issue":"1","key":"402_CR60","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clindermatol.2011.03.011","volume":"30","author":"R Gupta","year":"2012","unstructured":"Gupta R, Woodley DT, Chen M. Epidermolysis bullosa acquisita. Clin Dermatol. 2012;30(1):60\u20139.","journal-title":"Clin Dermatol"},{"key":"402_CR61","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/978-3-662-45698-9_59","volume-title":"Blistering diseases","author":"F Caux","year":"2015","unstructured":"Caux F, Prost-Squarcioni C. Mucous membrane pemphigoid. In: Murrell DF, editor. Blistering diseases. Sydney: Springer, Inc.; 2015. p. 565\u201371."},{"issue":"5","key":"402_CR62","doi-asserted-by":"crossref","first-page":"604","DOI":"10.2340\/00015555-1142","volume":"91","author":"HY Lee","year":"2011","unstructured":"Lee HY, Blazek C, Beltraminelli H, Borradori L. Oral mucous membrane pemphigoid: complete response to topical tacrolimus. Acta Derm Venereol. 2011;91(5):604\u20135.","journal-title":"Acta Derm Venereol"},{"key":"402_CR63","first-page":"527","volume":"84","author":"CS Foster","year":"1986","unstructured":"Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc. 1986;84:527\u2013663.","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"10","key":"402_CR64","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.ijom.2009.06.021","volume":"38","author":"M Carrozzo","year":"2009","unstructured":"Carrozzo M, Arduino P, Bertolusso G, et al. Systemic minocycline as a therapeutic option in predominantly oral mucous membrane pemphigoid: a cautionary report. Int J Oral Maxillofac Surg. 2009;38(10):1071\u20136.","journal-title":"Int J Oral Maxillofac Surg"},{"issue":"1","key":"402_CR65","first-page":"101","volume":"137","author":"P Musette","year":"2001","unstructured":"Musette P, Pascal F, Hoang-Xuan TM, et al. Treatment of cicatricial pemphigoid with pulse intravenous cyclophosphamide. Arch Dermatol. 2001;137(1):101\u20132.","journal-title":"Arch Dermatol"},{"issue":"2","key":"402_CR66","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/bjd.12041","volume":"168","author":"EM Munyangango","year":"2013","unstructured":"Munyangango EM, Le Roux-Villet C, Doan S, et al. Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid. Br J Dermatol. 2013;168(2):381\u201390.","journal-title":"Br J Dermatol"},{"issue":"1","key":"402_CR67","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1067\/mjd.2001.119100","volume":"46","author":"C Sacher","year":"2002","unstructured":"Sacher C, Rubbert A, Konig C, et al. Treatment of recalcitrant pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol. 2002;46(1):113\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"402_CR68","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/archderm.142.11.1457","volume":"142","author":"MJ Canizares","year":"2006","unstructured":"Canizares MJ, Smith DI, Conners MS, et al. Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients. Arch Dermatol. 2006;142(11):1457\u201361.","journal-title":"Arch Dermatol"},{"issue":"1","key":"402_CR69","first-page":"68","volume":"9","author":"JS Kennedy","year":"2010","unstructured":"Kennedy JS, Devillez RL, Henning JS. Recalcitrant cicatricial pemphigoid treated with the anti-TFF-alpha agent etanercept. J Drugs Dermatol. 2010;9(1):68\u201370.","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"402_CR70","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/sj.eye.6702948","volume":"21","author":"H John","year":"2007","unstructured":"John H, Wahllet A, Quinlan M. Successful biologic treatment of ocular mucous membrane pemphigoid with anti-TNF-alpha. Eye (Lond). 2007;21(11):1434\u20135.","journal-title":"Eye (Lond)."},{"issue":"1","key":"402_CR71","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2340\/00015555-0132","volume":"87","author":"S Prey","year":"2007","unstructured":"Prey S, Robert PY, Quinlan M. Treatment of ocular cicatricial pemphigoid with the tumour necrosis factor alpha antagonist etanercept. Acta Derm Venereol. 2007;87(1):74\u20135.","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"402_CR72","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/archdermatol.2011.54","volume":"147","author":"C Roux-Villet Le","year":"2011","unstructured":"Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol. 2011;147(7):843\u20139.","journal-title":"Arch Dermatol"},{"key":"402_CR73","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaad.2012.10.018","volume":"68","author":"S Shetty","year":"2013","unstructured":"Shetty S, Ahmed AR. Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature. J Am Acad Dermatol. 2013;68:499\u2013506.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"402_CR74","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","volume":"149","author":"E Daniel","year":"2010","unstructured":"Daniel E, Thorne JE, Newcomb CW, et al. Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010;149(3):423\u201332.","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"402_CR75","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clim.2003.11.002","volume":"111","author":"E Letko","year":"2004","unstructured":"Letko E, Miserocchi E, Daoud YJ, et al. A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. Clin Immunol. 2004;111(3):303\u201310.","journal-title":"Clin Immunol."},{"issue":"3","key":"402_CR76","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2340\/00015555-1065","volume":"91","author":"JH Kim","year":"2011","unstructured":"Kim JH, Kim YH, Kim SC. Epidermolysis bullosa acquisita: a retrospective clinical analysis of 30 cases. Acta Derm Venereol. 2011;91(3):307\u201312.","journal-title":"Acta Derm Venereol"},{"key":"402_CR77","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/978-3-662-45698-9_40","volume-title":"Blistering diseases","author":"C Prost-Squarcioni","year":"2015","unstructured":"Prost-Squarcioni C, Caux F. Epidermolysis bullosa acquisita. In: Murrell DF, editor. Blistering diseases. Sydney: Springer, Inc.; 2015. p. 405\u201312."},{"key":"402_CR78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/archderm.1971.04000130003001","volume":"103","author":"HH Roenigk","year":"1971","unstructured":"Roenigk HH, Ryan JG, Bergfeld WF. Epidermolysis bullosa acquisita: report of three cases and review of all published cases. Arch Dermatol. 1971;103:1\u201310.","journal-title":"Arch Dermatol"},{"key":"402_CR79","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1365-2133.2000.03368.x","volume":"142","author":"U Jappe","year":"2000","unstructured":"Jappe U, Zillikens D, Bonnekoh B, Gollnick H. Epidermolysis bullosa acquisita with ultraviolet radiation sensitivity. Br J Dermatol. 2000;142:517\u201320.","journal-title":"Br J Dermatol"},{"key":"402_CR80","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0190-9622(97)80352-0","volume":"36","author":"A Kubo","year":"1997","unstructured":"Kubo A, Hashimoto K, Inoue C, et al. Epidermolysis bullosa acquisita exacerbated by systemic estrogen and progesterone treatment and pregnancy. J Am Acad Dermatol. 1997;36:792\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"402_CR81","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/0190-9622(91)70107-D","volume":"24","author":"CJ Aprey","year":"1991","unstructured":"Aprey CJ, Elewski BE, Moritz DK, Gammon WR. Childhood epidermolysis bullosa acquisita. J Am Acad Dermatol. 1991;24:706\u201314.","journal-title":"J Am Acad Dermatol"},{"key":"402_CR82","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/archderm.1997.03890450070008","volume":"133","author":"C Callot-Mellot","year":"1997","unstructured":"Callot-Mellot C, Bodemer C, Caux F, et al. Epidermolysis bullosa acquisita in childhood. Arch Dermatol. 1997;133:1122\u20136.","journal-title":"Arch Dermatol"},{"key":"402_CR83","first-page":"301","volume":"116","author":"P Berbis","year":"1989","unstructured":"Berbis P, Privat Y. Value of colchicine in treating acquired epidermolysis bullosa. Ann Dermatol Venereol. 1989;116:301\u20137.","journal-title":"Ann Dermatol Venereol"},{"key":"402_CR84","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0190-9622(96)90013-4","volume":"34","author":"BB Cunningham","year":"1996","unstructured":"Cunningham BB, Kirchmann TT, Woodley D. Colchicine for epidermolysis bullosa acquisita. J Am Acad Dermatol. 1996;34:781\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"402_CR85","first-page":"139","volume":"9","author":"J Burger","year":"1992","unstructured":"Burger J, Gmur J, Bruckner-Tuderman L. Epidermolysis bullosa acquisita, a rare late complication of allogenic bone marrow transplantation? Bone Marrow Transplant. 1992;9:139\u201341.","journal-title":"Bone Marrow Transplant"},{"key":"402_CR86","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0190-9622(87)80239-6","volume":"16","author":"SM Connolly","year":"1987","unstructured":"Connolly SM, Sander HM. Treatment of epidermolysis bullosa acquisita with cyclosporine. J Am Acad Dermatol. 1987;16:890.","journal-title":"J Am Acad Dermatol."},{"key":"402_CR87","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1365-4632.2004.02245.x","volume":"44","author":"JC Maize Jr","year":"2005","unstructured":"Maize JC Jr, Cohen JB. Cyclosporine controls epidermolysis bullosa acquisita co-occurring with acquired factor VIII deficiency. Int J Dermatol. 2005;44:692\u20134.","journal-title":"Int J Dermatol"},{"key":"402_CR88","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/978-3-662-45698-9_61","volume-title":"Blistering diseases","author":"C Prost-Squarcioni","year":"2015","unstructured":"Prost-Squarcioni C, Caux F. Epidermolysis bullosa acquisita. In: Murrell DF, editor. Blistering diseases. Sydney: Springer, Inc.; 2015. p. 579\u201387."},{"key":"402_CR89","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.annder.2011.01.019","volume":"138","author":"C Roux-Villet Le","year":"2011","unstructured":"Le Roux-Villet C, Prost-Squarcioni C. Epidermolysis bullosa acquisita: literature review. Ann Dermatol Venereol. 2011;138:228\u201346.","journal-title":"Ann Dermatol Venereol"},{"key":"402_CR90","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1468-3083.2011.04205.x","volume":"26","author":"AR Ahmed","year":"2012","unstructured":"Ahmed AR, Gurcan HM. Treatment of epidermolysis bullosa acquisita with intravenous immunoglobulin in patients non-responsive to conventional therapy: clinical outcome and post-treatment long-term follow up. J Eur Acad Dermatol Venereol. 2012;26:1074\u201383.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"402_CR91","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0190-9622(97)80411-2","volume":"36","author":"H Kofler","year":"1997","unstructured":"Kofler H, Wambacher-Gasser B, Topar G, et al. Intravenous immunoglobulin treatment in therapy-resistant epidermolysis bullosa acquisita. J Am Acad Dermatol. 1997;36:331\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"402_CR92","first-page":"193","volume":"137","author":"VT Nguyen","year":"2001","unstructured":"Nguyen VT, Ndoye A, Bassler KD, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol. 2001;137(2):193\u2013206.","journal-title":"Arch Dermatol"},{"issue":"8","key":"402_CR93","first-page":"598","volume":"8","author":"J Zimmermann","year":"2010","unstructured":"Zimmermann J, Bahmer F, Rose C, et al. Clinical and immunopathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges. 2010;8(8):598\u2013605.","journal-title":"J Dtsch Dermatol Ges."},{"issue":"10","key":"402_CR94","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1001\/archdermatol.2012.1830","volume":"148","author":"S Leger","year":"2012","unstructured":"Leger S, Picard D, Ingen-Housz-Oro S, et al. Prognostic factors of paraneoplastic pemphigus. Arch Dermatol. 2012;148(10):1165\u201372.","journal-title":"Arch Dermatol"},{"issue":"4","key":"402_CR95","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1067\/mjd.2000.107488","volume":"43","author":"P Joly","year":"2000","unstructured":"Joly P, Richard C, Gilbert D, et al. Sensitivity and specificity of clinical, histologic, and immunologic features in the diagnosis of paraneoplastic pemphigus. J Am Acad Dermatol. 2000;43(4):619\u201326.","journal-title":"J Am Acad Dermatol"},{"key":"402_CR96","unstructured":"Anhalt GJ. Paraneoplastic pemphigus. Adv Dermatol. 1997;12:77\u201396 (discussion 7)."},{"issue":"4","key":"402_CR97","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1067\/mjd.2001.112222","volume":"44","author":"M Ohyama","year":"2001","unstructured":"Ohyama M, Amagai M, Hashimoto T, et al. Clinical phenotype and anti-desmoglein autoantibody profile in paraneoplastic pemphigus. J Am Acad Dermatol. 2001;44(4):593\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"402_CR98","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1440-0960.2012.00921.x","volume":"54","author":"AA Yong","year":"2013","unstructured":"Yong AA, Tey HL. Paraneoplastic pemphigus. Australas J Dermatol. 2013;54(4):241\u201350.","journal-title":"Australas J Dermatol"},{"key":"402_CR99","first-page":"193","volume":"137","author":"VT Nguyen","year":"2001","unstructured":"Nguyen VT, Ndoye A, Bassler KD, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome: a reappraisal of paraneoplastic pemphigus. Arch Dermatol. 2001;137:193\u2013206.","journal-title":"Arch Dermatol"},{"key":"402_CR100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1440-1843.2008.01397.x","volume":"14","author":"F Maldonado","year":"2009","unstructured":"Maldonado F, Pittelkow MR, Ryu JH. Constructive bronchiolitis associated with paraneoplastic autoimmune multi-organ syndrome. Respirology. 2009;14:129\u201333.","journal-title":"Respirology"},{"key":"402_CR101","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1111\/j.1365-2133.2003.05659.x","volume":"149","author":"OV Nikolskaia","year":"2003","unstructured":"Nikolskaia OV, Nousari CH, Anhalt GJ. Paraneoplastic pemphigus in association with Castleman\u2019s disease. Br J Dermatol. 2003;149:1143\u201351.","journal-title":"Br J Dermatol"},{"key":"402_CR102","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00432-010-0874-z","volume":"137","author":"J Zhang","year":"2011","unstructured":"Zhang J, Qiao QL, Chen XX, et al. Improved outcomes after complete resection of underlying tumors for patients with paraneoplastic pemphigus: a single-center experience of 22 cases. J Cancer Res Clin Oncol. 2011;137:229\u201334.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"18","key":"402_CR103","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199905063401805","volume":"340","author":"HC Nousari","year":"1999","unstructured":"Nousari HC, Deterding R, Wojtczack H, et al. The mechanism of respiratory failure in panaeoplastic pemphigus. N Engl J Med. 1999;340(18):1406\u201310.","journal-title":"N Engl J Med"},{"key":"402_CR104","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.ad.2010.06.012","volume":"101","author":"AB Cervini","year":"2010","unstructured":"Cervini AB, Tosi V, Kim SH, et al. Paraneoplastic pemphjigus or paraneoplastic autoimmune multiorgan syndrome: report of 2 cases in children and review of the literature. Actas Dermosifiliogr. 2010;101:879\u201386.","journal-title":"Actas Dermosifiliogr."},{"key":"402_CR105","first-page":"269","volume":"157","author":"L Borradori","year":"2001","unstructured":"Borradori L, Lombardi T, Samson J, et al. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20 (+) follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol. 2001;157:269\u201372.","journal-title":"Arch Dermatol"},{"key":"402_CR106","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","volume":"6","author":"M Hertl","year":"2008","unstructured":"Hertl M, Zillikens D, Borradori L, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin disease. J Dtsch Dermatol Ges. 2008;6:366\u201373.","journal-title":"J Dtsch Dermatol Ges."},{"key":"402_CR107","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1600-0609.2004.00280.x","volume":"75","author":"T Hohwy","year":"2004","unstructured":"Hohwy T, Bang K, Steiniche T, et al. Alemtuzumab-induced remission of both severe paraneoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment resistant B-cell chronic lymphocytic leukaemia. Eur J Haematol. 2004;75:206\u20139.","journal-title":"Eur J Haematol"},{"key":"402_CR108","first-page":"431","volume-title":"Dermatology","author":"L Borradori","year":"2012","unstructured":"Borradori L, Bernard P. Pemphigoid group. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors. Dermatology. 3rd ed. New York: Elsevier; 2012. p. 431\u201345.","edition":"3"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-016-0402-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-016-0402-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-016-0402-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T16:37:34Z","timestamp":1601138254000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-016-0402-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":108,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["402"],"URL":"https:\/\/doi.org\/10.1007\/s40266-016-0402-1","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10]]}}}